As key sensors detecting different danger signals, such as inflammatory stimuli and bacteria, the inflammasomes, and particularly the NLRP3 inflammasome, have been associated with a wide range of conditions, including IBD, Parkinson, type II diabetes, etc. [50,51] Preclinical models of intestinal inflammation, chronic pain and others, treated with inflammasome inhibitors have generated promising findings to pursue the next generation of inflammasome inhibitors into clinical trials [50,51,52]. This evidence concerns the gene NLRP3 and inflammation.